- Home
- VRTX
as 12-19-2024 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 119.6B | IPO Year: | 1991 |
| Target Price: | $519.12 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 30 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $378.00 - $519.88 | Next Earning Date: | 02-03-2025 |
| Revenue: | $10,625,800,000 | Revenue Growth: | 10.06% |
| Revenue Growth (this year): | 12.54% | Revenue Growth (next year): | 8.52% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Nov 15 '24 | Sell | $478.56 | 15 | $7,178.40 | 25,813 | |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Nov 11 '24 | Sell | $518.27 | 3,000 | $1,554,810.00 | 44,137 | |
| Kewalramani Reshma | VRTX | CEO & President | Nov 8 '24 | Sell | $515.00 | 15,198 | $7,826,970.00 | 75,772 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Oct 1 '24 | Sell | $461.66 | 999 | $461,198.34 | 16,651 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
9 hours ago
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug
Insider Monkey
9 hours ago
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’
MT Newswires
11 hours ago
Oppenheimer Downgrades Vertex Pharmaceuticals to Market Perform From Outperform; Shares Fall
Benzinga
12 hours ago
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Yahoo Finance Video
13 hours ago
Accenture, Robinhood and Coinbase, Vertex: Market Minute
MT Newswires
13 hours ago
RBC Capital Cuts Vertex Pharmaceuticals' Price Target to $400 From $451
MT Newswires
14 hours ago
Scotiabank Cuts Vertex Pharmaceuticals' Price Target to $426 From $486
Barrons.com
15 hours ago
Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise.
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.